Randomized controlled clinical trials of solifenacin on urination in patients with overactivity bladder

Objective To investigate the effect and safety of solifenacin on urination in patients with overactivity bladder (OAB) by randomized controlled clinical trials. Methods One hundred and eight patients with OAB were randomized divided into observation group and control group, each with 54 patients. The patients in two groups were respectively treated by solifenacin and tolterodine. After treatment for 8 weeks, the curative effect, urination and adverse reaction were compared between two groups. Results The total effective rate in observation group was 85.19%(46/54), in control group was 68.52%(37/54), there was significant difference (P<0.05). After treatment for 8 weeks, the frequency of urination for 24 h in observation group was less than that in control group[(7.2±3.1) times vs. (9.7±3.2) times], the levels of initial micturition desir bladder volume, maximum bladder pressure volume, maximum urine flow rate in observation group were better than those in control group: (215.4±34.6) ml vs. (184.1±42.1) ml, (341.6±24.5) ml vs. (283.4±24.8) ml, (20.4±5.8) ml/s vs. (16.8±7.1) ml/s, there were significant differences (P<0.05). The total scores and urgency scores of OAB symptom score (OABSS) in observation group were significantly lower than those in control group: (3.7±2.5) scores vs.(4.9±2.1) scores, (0.4±0.1) scores vs. (0.7±0.4) scores, P<0.05. The adverse reaction rate in observation group was 18.52% (10/54), in control group was 48.15% (26/54), there was significant difference (P<0.01). Conclusions Solifenacin can improve urination in OAB patients, and compared with tolterodine, it has higher efficacy and less adverse reaction. It is worthy of clinical application. Key words: Urinary bladder, overactive; Urination; Solifenacin; Tolterodine